Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing's sarcoma A673-xenograft growth and normalize tumor vascular architecture

Angiogenesis

Volumn 15, Issue 4, 2012, Pages 685-695

  Ackermann, Maximilian ^a   Morse, Brent A ^b   Delventhal, Vera ^a   Carvajal, Irvith M ^b   Konerding, Moritz A ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Adnectin; Antiangiogenesis; Corrosion casting; Ewing's sarcoma; Intussusceptive angiogenesis; Tumor microvasculature; Xenograft

Indexed keywords

ANGIOGENESIS INHIBITOR; AT 580PEG40; PEGDINETANIB; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; EWING SARCOMA; FEMALE; HUMAN; HUMAN CELL; MICROVASCULATURE; MONOTHERAPY; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UPREGULATION;

MURINAE;

EID: 84875051370     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-012-9294-9     Document Type: Article

References (33)

1. Scotlandi K, Remondini D, Castellani G, Manara MC, Nardi F, Cantiani L, Francesconi M, Mercuri M, Caccuri AM, Serra M, Knuutila S, Picci P (2009) Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J Clin Oncol 27(13):2209-2216 (Epub 2009 Mar 23).
2. Miser JS, Goldsby RE, Chen Z, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore SG, Rausen AR, Vietti TJ, Grier HE (2007) Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy-a report from the Children's Oncology Group. Pediatr Blood Cancer 49(7):894-900. (Pubitemid 350022441)
3. Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, Ludwig JA (2009) Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol 10(1-2):126-140 (Epub 2009 Jun 17).
4. Kelleher FC, Thomas DM (2012) Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours. Clin Sarcoma Res 2(1):6.
5. Bolontrade MF, Zhou RR, Kleinerman ES (2002) Vasculogenesis plays a role in the growth of Ewing's sarcoma in vivo. Clin Cancer Res 8(11):3622-3627. (Pubitemid 35340741)
6. Kreuter M, Paulussen M, Boeckeler J, Gerss J, Buerger H, Liebscher C, Kessler T, Jurgens H, Berdel WE, Mesters RM (2006) Clinical significance of vascular endothelial growth factor- A expression in Ewing's sarcoma. Eur J Cancer 42(12):1904-1911 (Epub 2006 Jul 7). (Pubitemid 44149095)
7. Strammiello R, Benini S, Manara MC, Perdichizzi S, Serra M, Spisni E, Picci P, Scotlandi K (2003) Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells. Horm Metab Res 35(11-12):675-684. (Pubitemid 38058171)
8. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ (2009) The insulin-like growth factor-1 receptor-targeting antibody, CP-751, 871, suppresses tumorderived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 69(19):7662-7671 (Epub 2009 Sep 29).
9. Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, Sankhala K, Furfine E, Gokemeijer J, Iacono L, Eaton C, Silver BA, Mita M (2011) Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 17(2):363-371.
10. Ackermann M, Carvajal IM, Morse BA, Moreta M, O'Neil S, Kossodo S, Peterson JD, Delventhal V, Marsh HN, Furfine ES, Konerding MA (2011) Adnectin CT-322 inhibits tumor growth and affects microvascular architecture and function in Colo205 tumor xenografts. Int J Oncol 38(1):71-80.
11. Emanuel SL, Engle LJ, Chao G, Zhu RR, Cao C, Lin Z, Yamniuk AP, Hosbach J, Brown J, Fitzpatrick E, Gokemeijer J, Morin P, Morse BA, Carvajal IM, Fabrizio D, Wright MC, Das Gupta R, Gosselin M, Cataldo D, Ryseck RP, Doyle ML, Wong TW, Camphausen RT, Cload ST, Marsh HN, Gottardis MM, Furfine ES (2011) A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs 3(1):38-48 (Epub 2011 Jan 1).
12. Kim SY, Toretsky JA, Scher D, Helman LJ (2009) The role of IGF-1R in pediatric malignancies. Oncologist 14(1):83-91 (Epub 2009 Jan 6).
13. Hlushchuk R, Riesterer O, Baum O, Wood J, Gruber G, Pruschy M, Djonov V (2008) Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am J Pathol 173(4): 1173-1185 (Epub 2008 Sep 11).
14. Weibel ER, Kistler GS, Scherle WF (1966) Practical stereological methods for morphometric cytology. J Cell Biol 30(1):23-38.
15. Filipovic N, Tsuda A, Lee GS, Miele LF, Lin M, Konerding MA, Mentzer SJ (2009) Computational flow dynamics in a geometric model of intussusceptive angiogenesis.Microvasc Res 78(3):286-293.
16. Zumkeller W (2001) IGFs and IGFBPs: surrogate markers for diagnosis and surveillance of tumour growth? Mol Pathol 54(5): 285-288. (Pubitemid 32928252)
17. Tombolan L, Orso F, Guzzardo V, Casara S, Zin A, Bonora M, Romualdi C, Giorgi C, Bisogno G, Alaggio R, Pinton P, De Pittà C, Taverna D, Rosolen A, Lanfranchi G (2011) High IGFBP2 expression correlates with tumor severity in pediatric rhabdomyosarcoma. Am J Pathol 179(5):2611-2624.
18. DuBois SG, Marina N, Glade-Bender J (2010) Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. Cancer 116(3):749-757.
19. BagleyRG, Kurtzberg L, WeberW, NguyenTH, Roth S, Krumbholz R, Yao M, Richards B, Zhang M, Pechan P, Schmid S, Scaria A, Kaplan J, Teicher BA (2011) sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther 10(3):404-415.
20. Gerber HP, Kowalski J, Sherman D, EberhardDA, Ferrara N (2000) Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60(22):6253-6258.
21. Dalal S, Berry AM, Cullinane CJ, Mangham DC, Grimer R, Lewis IJ, Johnston C, Laurence V, Burchill SA (2005) Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 11(6):2364-2378. (Pubitemid 40490198)
22. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64(11):3731-3736. (Pubitemid 38697278)
23. Konerding MA, Turhan A, Ravnic DJ, Lin M, Fuchs C, Secomb TW, Tsuda A, Mentzer SJ (2010) Inflammation-induced intussusceptive angiogenesis in murine colitis. Anat Rec (Hoboken) 293(5):849-857.
24. Döme B, Hendrix MJ, Paku S, Tóvári J, Tímár J (2007) Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 170(1):1-15. (Pubitemid 47339184)
25. Wnuk M, Hlushchuk R, Tuffin G, Huynh-Do U, Djonov V (2011) The effects of PTK787/ZK222584, an inhibitor of VEGFR and PDGFRb pathways, on intussusceptive angiogenesis and glomerular recovery from Thy1.1 nephritis. Am J Pathol 178(4):1899-1912.
26. Scotlandi K, Manara MC, Serra M, Marino MT, Ventura S, Garofalo C, Alberghini M, Magagnoli G, Ferrari S, Lopez Guerrero JA, Llombard-Bosch A, Picci P (2011) Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. Eur J Cancer 47(8): 1258-1266 (Epub 2011 Feb 21).
27. Kim SY, Toretsky JA, Scher D, Helman LJ (2009) The role of IGF 1R in pediatric malignancies. Oncologist 14(1):83-91 (Epub 2009 Jan 6).
28. Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM, Wolf E (2001) Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 61(24): 8601-8610. (Pubitemid 34013863)
29. Liou JM, Shun CT, Liang JT, Chiu HM, Chen MJ, Chen CC, Wang HP, Wu MS, Lin JT (2010) Plasma insulin-like growth factor binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J Clin Endocrinol Metab 95(4): 1717-1725 (Epub 2010 Feb 15).
30. Huang F, Hurlburt W, Greer A, Reeves KA, Hillerman S, Chang H, Fargnoli J, Graf Finckenstein F, Gottardis MM, Carboni JM (2010) Differential mechanisms of acquired resistance to insulinlike growth factor-i receptor antibody therapy or to a smallmolecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res 70(18):7221-7231 (Epub 2010 Aug 31).
31. Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, KangMH, Maris JM, Billups C, SmithMA, Houghton PJ (2011) Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS- 754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 56(4):595-603. doi:10.1002/pbc.22741 (Epub 2010 Dec 22).
32. Litzenburger BC, Kim HJ, Kuiatse I, Carboni JM, Attar RM, Gottardis MM, Fairchild CR, Lee AV (2009) BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells. Clin Cancer Res 15(1):226-237.
33. Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, Yee D (2010) Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 29(17):2517-2527 (Epub 2010 Feb 15).